Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo

Toyota,Hiroko; Yanase,Noriko; Yoshimoto,Takayuki; Harada,Mitsunori; Kato,Yasuki; Mizuguchi,Junichiro

doi:10.3892/or.2014.3603

Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo

Authors:
- Hiroko Toyota
- Noriko Yanase
- Takayuki Yoshimoto
- Mitsunori Harada
- Yasuki Kato
- Junichiro Mizuguchi
View Affiliations

Affiliations: Department of Immunology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-8402, Japan, Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, Shinjuku‑ku, Tokyo 160‑8402, Japan, NanoCarrier Co. Ltd., Kashiwa-shi, Chiba 277-0871, Japan
Published online on: November 12, 2014 https://doi.org/10.3892/or.2014.3603
Pages: 292-296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immunotherapy has gained special attention due to its specific effects on tumor cells and systemic action to block metastasis. We recently demonstrated that ovalbumin (OVA) conjugated to the surface of nanoparticles (NPs) (OVA‑NPs) can manipulate humoral immune responses. In the present study, we aimed to ascertain whether vaccination with OVA-NPs entrapping IL-7 (OVA-NPs-IL-7) are able to induce antitumor immune responses in vivo. Pretreatment with a subcutaneous inoculation of OVA-NPs delayed the growth of thymic lymphoma cells expressing a model tumor antigen OVA (E.G7-OVA), and OVA-NPs-IL-7 substantially blocked the growth of E.G7-OVA tumor cells, although NPs-IL-7 alone had a meager effect, as assessed by the mean tumor size and the percentage of tumor-free mice. However, pretreatment with OVA-NPs-IL-7 failed to reduce the growth of parental thymic tumor cells, suggesting that the antitumor effect was antigen-specific. A tetramer assay revealed that vaccination with OVA-NPs-IL-7 tended to enhance the proportion of cytotoxic T cells (CTLs) specific for OVA. When the tumor-free mice inoculated with OVA-NPs-IL-7 plus EG.7 cells were rechallenged with E.G7-OVA cells, they demonstrated reduced growth compared with that in the control mice. Thus, a single subcutaneous injection of OVA-NPs-IL-7 into mice induced tumor-specific and also memory-like immune responses, resulting in regression of tumor cells. Antigens on NPs entrapping IL-7 would be a promising carrier to develop and enhance immune responses, including humoral and cellular immunity as well as a method of drug delivery to a specific target of interest.

View Figures

View References

1	Sanlorenzo M, Vujic I, Posch C, et al: Melanoma immunotherapy. Cancer Biol Ther. 15:665–674. 2014. View Article : Google Scholar : PubMed/NCBI
2	Disis ML, Bernhard H and Jaffee EM: Use of tumour-responsive T cells as cancer treatment. Lancet. 373:673–683. 2009. View Article : Google Scholar : PubMed/NCBI
3	Yoo JW, Irvine DJ, Discher DE, et al: Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 10:521–535. 2011. View Article : Google Scholar : PubMed/NCBI
4	Radford KJ, Tullett KM and Lahoud MH: Dendritic cells and cancer immunotherapy. Curr Opin Immunol. 27:26–32. 2014. View Article : Google Scholar : PubMed/NCBI
5	Moore MW, Carbone FR and Bevan MJ: Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:777–785. 1988. View Article : Google Scholar : PubMed/NCBI
6	Oppenheim JJ: Cytokines: Past, present, and future. Int J Hematol. 74:3–8. 2001. View Article : Google Scholar : PubMed/NCBI
7	Christian DA and Hunter CA: Particle-mediated delivery of cytokines for immunotherapy. Immunotherapy. 4:425–441. 2012. View Article : Google Scholar : PubMed/NCBI
8	Katzman SD, Hoyer KK, Dooms H, et al: Opposing functions of IL-2 and IL-7 in the regulation of immune responses. Cytokine. 56:116–121. 2011. View Article : Google Scholar : PubMed/NCBI
9	Liu S, Lizée G, Lou Y, et al: IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 19:1213–1221. 2007. View Article : Google Scholar : PubMed/NCBI
10	Gou HF, Huang J, Shi HS, et al: Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One. 9:e857892014. View Article : Google Scholar : PubMed/NCBI
11	Oyewumi MO, Kumar A and Cui Z: Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 9:1095–1107. 2010. View Article : Google Scholar : PubMed/NCBI
12	Krishnamachari Y, Geary SM, Lemke CD, et al: Nanoparticle delivery systems in cancer vaccines. Pharm Res. 28:215–236. 2011. View Article : Google Scholar
13	Osada K, Christie RJ and Kataoka K: Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery. J R Soc Interface. 6(Suppl 3): S325–S339. 2009. View Article : Google Scholar : PubMed/NCBI
14	Matsumura Y and Kataoka K: Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100:572–579. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yanase N, Toyota H, Hata K, et al: OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis. Vaccine. 32:5918–5924. 2014. View Article : Google Scholar : PubMed/NCBI
16	Harada M, Ohuchi M, Hayashi T and Kato Y: Prolonged circulation and in vivo efficacy of recombinant human granulocyte colony-stimulating factor encapsulated in polymeric micelles. J Control Release. 156:101–108. 2011. View Article : Google Scholar : PubMed/NCBI
17	DeNardo DG, Andreu P and Coussens LM: Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 29:309–316. 2010. View Article : Google Scholar : PubMed/NCBI
18	Mahapatro A and Singh DK: Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology. 9:552011. View Article : Google Scholar : PubMed/NCBI
19	Andersen BM and Ohlfest JR: Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett. 325:155–164. 2012. View Article : Google Scholar : PubMed/NCBI
20	Manolova V, Flace A, Bauer M, et al: Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 38:1404–1413. 2008. View Article : Google Scholar : PubMed/NCBI
21	Möller P, Sun Y, Dorbic T, et al: Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer. 77:1907–1916. 1998. View Article : Google Scholar : PubMed/NCBI
22	Li J, Huston G and Swain SL: IL-7 promotes the transition of CD4 effectors to persistent memory cells. J Exp Med. 198:1807–1815. 2003. View Article : Google Scholar : PubMed/NCBI
23	Schluns KS, Kieper WC, Jameson SC and Lefrançois L: Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol. 1:426–432. 2000. View Article : Google Scholar
24	Rochman Y, Spolski R and Leonard WJ: New insights into the regulation of T cells by γ_c family cytokines. Nat Rev Immunol. 9:480–490. 2009. View Article : Google Scholar : PubMed/NCBI
25	Hussein MR: Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br J Dermatol. 153:18–21. 2005. View Article : Google Scholar : PubMed/NCBI
26	Egeblad M, Nakasone ES and Werb Z: Tumors as organs: Complex tissues that interface with the entire organism. Dev Cell. 18:884–901. 2010. View Article : Google Scholar : PubMed/NCBI
27	de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 6:24–37. 2006. View Article : Google Scholar : PubMed/NCBI